ArticleBioengineering (Basel, Switzerland)2026
TeleGlaukos: A Clinician-Led Adaptive Telemonitoring Platform for Hybrid Glaucoma Care.
Article in Bioengineering (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glaucoma requires continuous surveillance, sustained treatment adherence, and timely recognition of postoperative or treatment-related complications. Conventional outpatient follow-up provides structured clinical assessment but offers limited visibility of symptoms between appointments. This study describes TeleGlaukos, a clinician-led adaptive telemonitoring platform designed for hybrid perioperative and therapeutic glaucoma care. Its principal innovation is a configurable protocol engine that transforms static symptom forms into patient-specific workflows through conditional questions, symptom-triggered branching, medication reminders, rule-based alerts, and bidirectional clinician-patient communication. The platform was implemented as a Progressive Web App connected to a modular Django backend through RESTful APIs and WebSocket-enabled communication. The clinical pilot cohort comprised 30 glaucoma patients followed between May 2025 and April 2026. The wider platform environment contained 95 registered accounts: 30 glaucoma patients, 10 ophthalmologists, 10 research or administrative users, 20 development and testing accounts, and 25 non-pilot registered users. Across the platform, 737 engaged sessions, 1329 events, 30 bidirectional messages, and 186 questionnaire responses were recorded. Structured monitoring identified suspected treatment-related adverse reactions in two patients, prompting earlier clinical reassessment and treatment adjustment. Usability was assessed in 22 respondents (18 patients and 4 ophthalmologists), yielding a mean System Usability Scale score of 79.43 ± 17.98 (95% CI: 71.46-87.40), corresponding to a Good adjective rating and an Acceptable usability range; internal consistency was high (Cronbach's alpha = 0.882). The artificial intelligence-assisted module remained exploratory and was not evaluated as an autonomous clinical component. TeleGlaukos demonstrated technical feasibility, favourable perceived usability, and the capacity of adaptive symptom workflows to surface clinically relevant signals between visits. Larger multicentre studies are required to evaluate effectiveness, safety, adherence, workflow burden, and cost-effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.